(2S,3S,4R)-1-苄基-2-(羟甲基)吡咯烷-3,4-二醇 | 117770-04-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2S,3S,4R)-1-苄基-2-(羟甲基)吡咯烷-3,4-二醇
• 英文名称: N-benzyl-1,4-dideoxy-1,4-imino-L-ribitol
• 英文别名: 1,4-dideoxy-1,4-benzylimino-L-ribitol；(2S,3S,4R)-1-benzyl-2-(hydroxymethyl)pyrrolidine-3,4-diol
• CAS: 117770-04-4
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.272
• InChiKey: SBDAWMSBMQBJRA-TUAOUCFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  (2S,3S,4R)-N-benzyl-2-hydroxymethyl-3,4-O-isopropylidenepyrrolidine-3,4-diol 在 三氟乙酸 作用下， 反应 20.0h， 生成 (2S,3S,4R)-1-苄基-2-(羟甲基)吡咯烷-3,4-二醇
  参考文献：
  名称：

  Synthesis from d-mannose of 1,4-dideoxy-1,4-imino-l-ribitol and of the α-mannosidase inhibitor 1,4-dideoxy-1,4-imino-d-talitol

  摘要：

  DOI：

  10.1016/s0040-4020(01)81717-8

文献信息

• Heterocyclic compounds for inhibiting virus
  申请人：Monsanto Company

  公开号：EP0322395A1

  公开（公告）日：1989-06-28

  Various heterocyclic compounds, namely (a) the N-methyl derivative of di(hydroxymethyl)-dihydroxy­pyrrolidine, (b) 1,4-dideoxy-1,4-imino-L-arabinitol, (c) 1,4-dideoxy-1,4-imino-L-ribitol, (d) 1,4-dideoxy-1,4-imino-D-ribitol, (e) 1,4-dideoxy-1,4-imino-(N-methyl)-L-arabinitol, (f) 1,4-dideoxy-1,4-imino-(N-methyl)-D-ribitol, (g) 1,4-dideoxy-1,4-benzylimino-L-ribitol, (h) 1,4-dideoxy-1,4-imino-D-talitol, (i) the N-methyl derivative of deoxymannojirimycin, (j) 1,5-dideoxy-1,5-imino-L-fuconolactam, (k) 1,5-dideoxy-1,5-imino-(N-methyl)-L-fucitol, (l) 1,5-dideoxy-1,5-imino-(N-ω-methyl caproate)-L-fucitol, and their pharmaceutically acceptable salt derivatives are useful as inhibiting agents of human immunodeficiency virus. Compounds (a), (e), (j), (k) and (l) are new.

  各种杂环化合物，即 (a) 二（羟甲基）-二羟基吡咯烷的 N-甲基衍生物、 (b) 1,4-二脱氧-1,4-亚氨基-L-阿拉伯糖醇、 (c) 1,4-二脱氧-1,4-亚氨基-L-核糖醇、 (d) 1,4-二脱氧-1,4-亚氨基-D-核糖醇、 (e) 1,4-二脱氧-1,4-亚氨基-(N-甲基)-L-阿拉伯糖醇、 (f) 1,4-二脱氧-1,4-亚氨基-(N-甲基)-D-核糖醇、 (g) 1,4-二脱氧-1,4-苄基亚氨基-L-核糖醇、 (h) 1,4-二脱氧-1,4-亚氨基-D-谷糖醇、 (i) 脱氧曼尻霉素的 N-甲基衍生物、 (j) 1,5-二脱氧-1,5-亚氨基-L-岩藻内酰胺、 (k) 1,5-二脱氧-1,5-亚氨基-(N-甲基)-L-岩藻糖醇、 (l) 1,5-二脱氧-1,5-亚氨基-(N-ω-甲基己酸酯)-L-岩藻糖醇、 及其药学上可接受的盐衍生物可用作人类免疫缺陷病毒的抑制剂。化合物(a)、(e)、(j)、(k)和(l)是新化合物。
• FLEET, GEORGE W. J.;SON, JONG CHAN;GREEN, DONOVAN ST. C.;DI, BELLO ISABEL+, TETRAHEDRON, 44,(1988) N 9, 2649-2655
  作者：FLEET, GEORGE W. J.、SON, JONG CHAN、GREEN, DONOVAN ST. C.、DI, BELLO ISABEL+

  DOI：——

  日期：——
• TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES
  申请人：De Moor Olivier

  公开号：US20110237538A1

  公开（公告）日：2011-09-29

  Described are various compounds, in particular iminosugars, and methods for the treatment of proteostatic diseases, in particular lysosomal storage disorders. The compound may be a pharmacoperone of an enzyme selected from: (a) Acid alpha-glucosidase; (b) Acid beta-glucosidase; (c) glucocerebrosidase; (d) alpha-Galactosidase A; (e) Acid beta-galactosidase; (f) beta-Hexosaminidase A; (g) beta-Hexosaminidase B; (h) Acid sphingomyelinase; (i) Galactocerebrosidase; (j) Acid ceramidase; (k) Arylsulfatase A; (l) alpha-L-Iduronidase; (m) Iduronate-2-sulfatase; (n) Heparan N-sulfatase; (o) alpha-N-Acetylglucosaminidase; (p) Acetyl-CoA: alpha-glucosaminide N-acetyltransferase; (q) N-Acetylglucosamine-6-sulfate sulfatase; (r) N-Acetylgalactosamine-6-sulfate sulfatase; (s) Acid beta-galactosidase; (t) Arylsulfatase B; (u) beta-Glucuronidase; (v) Acid alpha-mannosidase; (w) Acid beta-mannosidase; (x) Acid alpha-L-fucosidase; (y) Sialidase; and (z) alpha-N-acetylgalactosaminidase.
• US5043416A
  申请人：——

  公开号：US5043416A

  公开（公告）日：1991-08-27
• US4999360A
  申请人：——

  公开号：US4999360A

  公开（公告）日：1991-03-12